MedTrace Logo

New Inflammation Markers for Distinguishing Uterine Adenomyosis and Leiomyoma

NCT02997787 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2016-12-26

No results posted yet for this study

Summary

Both pelvic masses and preoperative diagnosis of them have still continued as an important investigation subject. It is important to discriminate the diagnoses of leiomyoma and adenomyosis before operation especially among infertile patients. Neoplasms can alter systemic or local immune response in their originating area.Neutrophil to lymphocyte ratio (NLR) and platelet to lymphocyte ratio (PLR) can be readily determined by using of complete blood counter test (CBC). A high NLR has been shown in systemic inflammation, some gynecologic and gastrointestinal cancers and some cardiovascular diseases.

The investigators aim to investigate using new inflammation markers, NLR and PLR, whether they are useful to discriminate between adenomyosis and leiomyoma. As far as is known, there have been no previous reports about the association among NLR, PLR, adenomyosis and leiomyoma.

Conditions

Sponsors & Collaborators

  • Kayseri Education and Research Hospital

    lead OTHER_GOV

Principal Investigators

  • Yusuf Madendag · Kayseri Education and Research Hospital

Eligibility

Min Age
35 Years
Max Age
60 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-01-31
Primary Completion
2016-10-31
Completion
2016-11-30

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02997787 on ClinicalTrials.gov